Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Several radiopharmaceuticals have recently been shown to have a considerable affinity for malignant tissue. All the tumor-seeking radiopharmaceuticals in current use are nonspecific and may also be picked up by benign tumors and infectious processes, including abscess and granuloma. The sensitivity of the tumor-imaging procedure depends on the radiopharmaceutical employed, the type of tumor, its size and location, and previous or current treatment. Gallium-67 citrate (67Ga), the most widely used tumor-seeking radiopharmaceutical, seems to have its greatest value in detecting bronchogenic carcinomas irrespective of cell type. The sensitivity for lung cancer in 489 studies was 93 per cent. Gallium-67 is also of great value in the staging of Hodgkin's disease, in which its sensitivity is 87 per cent. Non-Hdgkin's lymphomas are detected with only slightly lower sensitivity. There is, in fact, evidence that 67Ga is at least complemenatry, if not more sensitive than lymphangiography, in the staging of lymphoma. However, adenocarcinomas originating in the gastrointestinal tract are detected by 67Ga with a sensitivity of only about 40 per cent, whereas various chelates of bleomycin (including 111In-Bleo, 99mTc-Bleo and 57Co-Bleo) detect adenocarcinoma of the gastrointestinal tract with considerably higher sensitivity. In the few studies available comparing bleomycin chelates, 57Co-Bleo and 99mTc-Bleo appear to be more sensitive in detecting tumor than 111In-Bleo. Other tumor-seeking radiopharmaceuticasl which have been employed with somewhat less success include selenium compounds, labeled pyrimidines, several inorganic cations, lanthanide chelates and labeled proteins. Yet to be evaulated clinically is the efficacy of radiolabeled antibodies which are specific for tumor antigens, such as 131I-anti-CEA (carcinoembryonic antigen).
 ...
PMID:Cancer diagnosis. The role of tumor-imaging radiopharmaceuticals. 5 31

The haematologic effects of radioimmunotherapy (RAIT) in cancer patients have been studied in order to better understand the aetiology of RAIT-associated myelosuppression. Evaluations were performed on patients treated with 131I-anti-carcinoembryonic antigen (CEA) and 131I-LL2, a monoclonal antibody (MAb) reactive with non-Hodgkin's B-cell lymphoma. Both groups of patients experienced decreases in WBC and platelets. Nadirs were observed 42-51 d post first injection in the lymphoma patients, and 49-66 d post first injection (30-43 d post high-dose therapeutic injection) in the carcinoma patients. Within the WBC population, B cells were the most radiosensitive. The evaluations of the binding of these MAbs to peripheral blood cells and the effect of RAIT on lymphocyte subpopulations indicated a drop of 26-92% in the percentage of B lymphocytes within 1 week following treatment with both 131I-LL2 and 131I-anti-CEA MAbs even though only LL2 binds to B cells. The percentage of T lymphocytes was not affected by the 131I-antibody treatments. These observations suggest that the marked drop in circulating B lymphocytes and platelets after the administration of radioiodinated antibodies is a nonspecific radiation effect, and not necessarily related to the binding of MAb to normal B cells. Thus, among WBCs, B cells are uniquely radiosensitive, and will be unusually affected by antibody-directed internal radiation.
 ...
PMID:Haematological effects of radioimmunotherapy in cancer patients. 153 12

The cytologic and histopathologic findings in a patient with Hodgkin's lymphoma, mixed cellularity type, and a malignant pleural effusion are presented. The consistency of staining with a battery of immunoperoxidase monoclonal antibody stains, including leukocyte common antigen, Leu-M1, UCHL1 and L26, was examined on sections of formalin-fixed lymph nodes and alcohol-fixed pleural fluid cell blocks. In addition, these same tissues were stained with carcinoembryonic antigen, B72.3, cytokeratin and epithelial membrane antigen immunoperoxidase antibodies to differentiate the tumor cells from reactive mesothelial cells and adenocarcinoma cells. The results on the pleural fluid specimens were consistent with what is known of the immunohistochemical staining properties of Hodgkin's lymphoma cells in lymph nodes.
 ...
PMID:Malignant pleural effusion in Hodgkin's lymphoma. Report of a case with immunoperoxidase studies. 171 Apr 3

Neurological disorders associated with a malignant neoplasm, which is not caused by a direct effect such as metastasis, infiltration or compression, is called carcinomatous neuromyopathy. Subacute cerebellar degeneration recognized in this category is characterized by acutely or subacutely progressive cerebellar ataxia and widespread loss of Purkinje cells. There have been several reports of subacute cerebellar degeneration in lung carcinoma, ovarian carcinoma and Hodgkin's disease, but rare in urogenital malignancies. We present a patient with neurological disorder considered subacute cerebellar degeneration associated with HCG-beta positive seminoma. A 29-year-old man noticed a left intrascrotal mass in the summer of 1984. The mass began to grow in April, 1985 and diplopia, gait disturbance and dysarthria appeared late in May. He consulted our hospital on July 20, 1985. Serum human chorionic gonadotropin (HCG)-beta was elevated to 200 ng/ml but alpha-fetoprotein and carcinoembryonic antigen were normal. Left high orchiectomy was performed and the tumor was diagnosed histologically as typical seminoma. Bulky metastatic tumor was recognized in retroperitoneum on abdominal CT but brain CT was normal. VAB VI chemotherapy was performed. The retroperitoneal metastatic tumor disappeared and HCG-beta was normalized and complete remission achieved, but cerebellar symptoms still remain 14 months after remission. This case is considered to be subacute cerebellar degeneration associated with seminoma and is the second case with testicular carcinoma reported.
 ...
PMID:[Subacute cerebellar degeneration with HCG-beta positive seminoma of the testis]. 245 60

Over 100 patients have received cyclic treatment with polyclonal 131I labeled anti-ferritin and anti-carcinoembryonic antigen (CEA) antibodies from different animal species (rabbit, pig, cynomolgous monkey, bovine, and baboon). Because survival was prolonged from original cyclic treatment, retreatment with original antibodies (recycling) became a necessary consideration. An assay using autoradiography of Ouchterlony gels, with diffusion of patients' sera against the varied radiolabeled antibodies, was developed to detect anti-antibody precipitin bands. Anti-antibody could be detected with a sensitivity to the 60 ng level. Sera from 35 patients given from 1 to 7 separate cycles (2 injections/week, total antibody 6 mg/cycle) of radiolabeled foreign antibody were studied for the production of anti-antibodies. Anti-antibodies were detected in 11 of 22 primary hepatoma patients studied, 3 of 4 intrahepatic biliary cancer patients, and 0 of 9 Hodgkin's disease patients. In all but two of the patients, the anti-antibodies produced were specific for the species used in the treatment of the patient. Eight patients were reinjected (recycled) with previously used antibodies and the presence or absence of precipitin bands correlated with the ability of these antibodies to deposit in the tumor or to be rapidly degraded. The importance of this assay is its simplicity, sensitivity, and the rapid detection of anti-antibody activity for patients requiring treatment with radiolabeled antibodies.
 ...
PMID:Detection of specific anti-antibodies in patients treated with radiolabeled antibody. 301 17

Serum neuron-specific enolase (NSE) was evaluated in a number of malignant tumours. It was elevated (greater than 12.5 micrograms l-1) in 13/17 (76.5%) patients with extensive small-cell lung carcinoma and in none of the three patients with limited disease. Of patients with carcinoma of the breast 4/12 (33.3%) had elevated concentrations. Normal concentrations were found in patients with non-Hodgkin's lymphoma (19) and Hodgkin's disease (15), carcinoma of the cervix (2), CSF and serum (5) of patients with gestational trophoblastic disease (with definite nervous system involvement). Comparative serial studies of NSE and carcinoembryonic antigen (CEA) concentrations were done in 15 patients with small-cell lung cancer (SCLC). Of these 7/15 (46.7%) had elevated pre-treatment concentrations of both CEA and NSE, 1/15 (6.7%) had CEA elevated only, while 2/15 (13.3%) had NSE alone elevated. Of those patients with normal pre-treatment marker concentrations 3/5 (60%) had elevated markers on recurrence. The mean survival period was 61.9 weeks; 66.8 weeks for the marker-negative group and 44.6 weeks for the marker-positive (both NSE and CEA) group. Combined NSE and CEA evaluation provide additional means of monitoring SCLC.
 ...
PMID:Neuron-specific enolase (NSE) as a tumour marker and comparative evaluation with carcinoembryonic antigen (CEA) in small-cell lung cancer. 303 5

We have assessed the diagnostic value of the determination of cerebrospinal fluid lactate dehydrogenase, carcinoembryonic antigen, beta 2-microglobulin, beta-glucuronidase and total protein, using linear discriminant analysis, in detecting central nervous system metastases from extracranial malignancies. We conclude that, using these tests, it is impossible to differentiate between control individuals and patients with brain or epidural metastases. Leptomeningeal dissemination from either solid tumours or non-Hodgkin lymphoma could be differentiated from control individuals and patients with brain or epidural metastases. In this differentiation it is essential that bacterial, fungal or tuberculous meningitis be excluded from the differential diagnosis by other diagnostic procedures. The combination of beta-glucuronidase and beta 2-microglobulin provides almost the same diagnostic information as the combination of all parameters.
 ...
PMID:Tumour markers in the cerebrospinal fluid of patients with central nervous system metastases from extracranial malignancies. 340 30

Monoclonal antibodies to different markers can facilitate the diagnosis of T and B cell lymphomas, histiocytic lymphomas, malignant histiocytosis, and Hodgkin's disease. The B-cell lymphomas can be identified specifically by monoclonal anti-idiotype antibodies. Monoclonal antibodies are produced to defined markers like carcinoembryonic antigen (CEA) in colon carcinomas and other antigens especially of breast and ovarian carcinomas. When conjugated with 123I, monoclonal antibodies can be used to detect tumors by emission computerized tomography. Chromogranins are markers for neuroendocrine tumors, and they can be identified by monoclonal antibodies. More recently monoclonal antibodies have been produced to ras gene product p21, present in breast and colon carcinoma cells.
 ...
PMID:Monoclonal antibodies to detect markers specific for tumors. 361 97

Four cases of lymphoma of the breast are described seen over a period of 2 years amongst 362 cases of breast carcinoma and one of carcinosarcoma. All four were diffuse non-Hodgkin's lymphomas, two of IgM-Kappa secreting follicle centre cell and two of histiocyte origin. Routine histological and enzyme histochemical methods were unhelpful but the application of a panel of antisera for the demonstration of immunoglobulin heavy and light chains, lysozyme, alpha-1-antitrypsin as well as carcinoembryonic antigen and epithelial membrane antigen, enabled a confident diagnosis to be made. Primary lymphoma of the breast may not be a rare disease and the possibility exists that it is misdiagnosed as anaplastic carcinoma as indeed two of these cases were on the initial biopsies. Correct diagnosis is essential so that appropriate treatment may be applied.
 ...
PMID:Primary lymphoma of the breast. 392 71

Serum lipid-bound sialic acid (LSA) was measured with a recently described procedure in 108 healthy subjects and in 138 patients with a variety of solid tumors and hematologic malignancies. At the time of serum sampling, 128 patients had active disease and 10 patients had no evidence of disease. LSA was elevated in 104 of 128 (81.2%) patients with active disease, while carcinoembryonic antigen, analyzed in 74, was elevated only in 21 (28.4%) (P less than 0.05). Sensitivity of the serum LSA test ranged from 66% for breast and gastrointestinal cancer to 92% for lung cancer. In patients with lung cancer, ovarian cancer or Hodgkin's disease, LSA was correlated with the extent of disease and it also proved to be useful in following the course of disease. Our preliminary data indicate that this test can be used as a monitor of tumor burden.
 ...
PMID:Lipid bound sialic acid in cancer patients. 400 46


1 2 3 Next >>